Skip to main content
SpringerLink
Log in
Book cover

Prostatakarzinom — urologische und strahlentherapeutische Aspekte pp 3–44Cite as

Pathologische Anatomie maligner Tumoren der Prostata

  • Chapter

  • 34 Accesses

Zusammenfassung

Im jungen Erwachsenenalter besitzt die etwa 20 g schwere Prostata annähernd die Größe einer Kastanie mit der Form eines Konus, dessen Basis dem Blasenhals und dessen Apex dem Diaphragma urogenitale zugewandt ist [62]. Die prostatische Urethra durchzieht das Organ mit einem nach ventral offenen stumpfen Winkel von etwa 140-150°. Die Prostata wird unter pragmatischen Gesichtspunkten in 2 Zonen eingeteilt: in eine innere und in eine äußere Zone, letztere macht beim jungen Erwachsenen mit etwa 90% die Hauptmasse der Prostata aus [69, 213]. Nach einem verfeinerten Konzept von McNeal [150], das klinische und funktionelle Gesichtspunkte berücksichtigt, werden 4 anatomische Zonen in der Prostata abgegrenzt (s. Abb. 1.1):

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abrahamsson PA, Wadstrom LB, Alumets J, Falkmer S, Grimelius L (1987) Peptid hormone and serotonin-immunoreactive tumor cells in carcinoma of the prostate. Pathol Res Pract 182: 298–307.

    PubMed  CAS  Google Scholar 

  2. Alanen KA, Kuopio T, Koskinen PJ, Nevalainen TJ (1996) Immunohistochemical labelling for prostate specific antigen in nonprostatic tissues. Path Res Pract 192: 233–237.

    PubMed  CAS  Google Scholar 

  3. Albertsen PC, Fryback DG, Storer Be, Kolon TF, Fine J (1995) Long term survival among men with conservatively treated localized prostate cancer. JAMA 274: 626–631.

    PubMed  CAS  Google Scholar 

  4. Amin MB, Grignon D, Bostwick D, Reuter V, Troncoso P, Ayala AG (1996) Recommendations for the reporting of resected prostate carcinomas. Association of directors of anatomic and surgical pathology. Am J Clin Pathol 105: 667–670.

    CAS  Google Scholar 

  5. Aprikian AG, Cordon-Cardo C, Fair WR, Reuter VE (1993) Characterisation of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 71: 3952–3965.

    PubMed  CAS  Google Scholar 

  6. Asmar L, Gehan EA, Newton WA, Webber BL, Marsden HB, van Unnik AJM et al. (1994) Agreement among and within groups of pathologists in the classification of rhabdomyosarcoma and related childhood sarcomas. Report of aninternational study of four pathology classifications. Cancer 74: 2579–2588.

    CAS  Google Scholar 

  7. Ayala AG, RO JY, Babaian RJ, Troncoso P, Grignon DJ (1989) The prostatic capsule: does it exist? Its importance in the staging and treatment of prostatic carcinoma. Am J Surg Pathol 13: 21–27.

    PubMed  CAS  Google Scholar 

  8. Badalament RA, Miller MC, Peller PA, Young DC, Bahn DK, Kochie P et al. (1996) An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 156:1375–1380.

    PubMed  CAS  Google Scholar 

  9. Bain GO, Koch M, Hanson J (1982) Feasibility of grading prostate carcinomas. Arch Pathol Lab Med 106:265–267.

    Google Scholar 

  10. Bartha R, Altwein JE (1997) Das Prostatakarzinom in den Print- Medien. Akt Urol 28:1–3.

    Google Scholar 

  11. Bartha R, Griffiths K, Altwein JE (1996) Der Einfluß nutritiver und non- nutritiver Nahrungsinhaltsstoffe auf die Inzidenz des Prostatakarzinoms. Akt Urol 27: 373–380.

    Google Scholar 

  12. Bastacky SJ, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI (1995) Pathological features of hereditary prostate cancer. J Urol 153: 987–992.

    PubMed  CAS  Google Scholar 

  13. Bauer JJ, Sesterhenn IA, Mostofi FK, Mc Leod DG, Srivastava S, Moul JW (1996) Elevated levels of apoptosis regulator proteins P53 and bcl- 2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol 156:1511–1516.

    PubMed  CAS  Google Scholar 

  14. Boeking A, AuffermannW (1987) Cytological grading of therapy- induced tumorregression in prostatic carcinoma: proposal of a new system. Diagn Cytopathol 3:108–111.

    Google Scholar 

  15. Boeking A, Sommerkamp H (1981) Histologisches Malignitätsgrading des Prostatakarzinoms. Pro- gnostische Validität, Reproduzierbarkeit und Repräsentativität. Verh Dtsch Ges Urol 32: 63–65.

    Google Scholar 

  16. Bookstein R, Allred DC (1993) Recessive oncogenes. Cancer 71 (Suppl): 1179–1186.

    PubMed  CAS  Google Scholar 

  17. Bookstein R, Mac Grogan D, Hilsenbeck SG, Sharkey F, Allred DC (1993) p53 is mutated in a subset of advanced stage prostate cancers. Cancer Res 53: 3369–3373.

    PubMed  CAS  Google Scholar 

  18. Bostwick DG (1992) Prostatic intraepithelial neoplasia(PIN): current concepts. J Cell Biochem 16: 10–19.

    Google Scholar 

  19. Bostwick DG (1994) Gleason grading of prostatic needle biopsies: correlation with grade in 316 matched prostatectomies. Am J Surg Pathol 18: 796–803.

    PubMed  CAS  Google Scholar 

  20. Bostwick DG (1996) Chapter 2: pathology of prostate cancer. In: Ernsthoff MS, Heaney JA, Peschel R (eds) Urologie cancer. Blackwell, Cambridge(USA London Paris Berlin Wien, pp 15–47.

    Google Scholar 

  21. Bostwick DG (1997) Staging prostate cancer — 1997: current methods and limitations. Eur Urol 32(Suppl 3): 2–14.

    PubMed  Google Scholar 

  22. Bostwick DG (1997) Neoplasms of the prostate. In: Bostwick DG, Eble JN (eds) Urological surgical pathology Mosby, St.Louis Baltimore Boston, pp 343–421.

    Google Scholar 

  23. Bostwick DG, Brawer MK (1987) Prostatic intraepithelial neoplasia and early invasion in prostatic cancer. Cancer 59: 788–794.

    PubMed  CAS  Google Scholar 

  24. Bostwick DG, Egbert BM, Fajardo LF (1982) Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol 6: 501–505.

    Google Scholar 

  25. Bostwick DG, Kindrachuk RW, Rouse RV (1985) Prostatic adenocarcinoma with endometroid features. Clinical, pathological and ultrastructural findings. Am J Surg Pathol 9: 595–609.

    PubMed  CAS  Google Scholar 

  26. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP (1992) The association of benign prostatic hyperplasia and cancer of the prostate. Cancer 70: 291–301.

    PubMed  CAS  Google Scholar 

  27. Bostwick DG, Algaba F, Amin HB, Ayala A, Eble J, Goldstein N et al. (1994) Consensus statement on terminology: recommendation to use atypical adenomatous hyperplasia in place of adenosis of the prostate. Am J Surg Pathol 18:1069–1070.

    PubMed  CAS  Google Scholar 

  28. Bostwick DG, Dousa MK, Crawford BG, Wollan PC (1994) Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma. Am J Surg Pathol 18:1240–1246.

    PubMed  CAS  Google Scholar 

  29. Bova GS, Carter BS, Bussemakers MJG, Emi M, Fujiwara Y, Kyprianou N et al. (1993) Homozygous deletion and frequent allelic loss of chromosome 8 p 22 loci in human prostate cancer. Cancer Res 53:3869–3873.

    PubMed  CAS  Google Scholar 

  30. Brawer MK (1996) Quantitative microvessel density. A staging and prognostic marker for human prostatic carcinoma. Cancer 78: 345–349.

    CAS  Google Scholar 

  31. Brawer MK, Peehl DM, Stamey TA, Bostwick DG (1985) Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res 45: 3663–3667.

    PubMed  CAS  Google Scholar 

  32. Brawer MK, Nagle RB, Pitts W, Freiha F, Gamble SC (1989) Keratin immunoreactivity as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostate. Cancer 63: 454–460.

    PubMed  CAS  Google Scholar 

  33. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA (1994) Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 73: 678–687.

    CAS  Google Scholar 

  34. Brawer MK, Jonsson E, Gibbons RP, Deering RE, Bigler SA, Preston SD (1994) Extent of prostate neovascularity predicts progression in patients with pathologic stage C adenocarcinoma treated with radical prostatectomy. J Urol 151(Suppl 246): 289 A.

    Google Scholar 

  35. Brennick JB, O’Connell J, Dickersin GR, Pilch BZ, Young RH (1994) Lipofuscin pigmentation (so called »melanosis«) of the prostate. Am J Surg Pathol 18: 446–454.

    PubMed  CAS  Google Scholar 

  36. Bussemakers MJG, van Moorselaar RJA, Giroldi LA, Ichikawa T, Isaacs JT, Takeichi M et al. (1992) Decreased expression of E-Cadherin in the progression of rat prostatic cancer. Cancer Res 52: 2916–2922.

    PubMed  CAS  Google Scholar 

  37. Carmichael MJ, Veltri RW, Partin AW, Miller MC, Walsh PC, Epstein JI (1995) Deoxyribonucleic acid ploidy analysisas a predictor of recurrence following radical prostatectomy for stage T2 disease. J Urol 153:1015–1019.

    PubMed  CAS  Google Scholar 

  38. Carter BS, Bova GS, Beaty TH, Steinberg GD, Childs B, Isaacs WB, Walsh PC (1993) Hereditary prostate cancer: epidemiologic and clinical features. J Urol 150: 797–802.

    PubMed  CAS  Google Scholar 

  39. Carter HB, Piantadosi S, Isaacs JT (1990) Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 143: 742–746.

    PubMed  CAS  Google Scholar 

  40. Castagnaro M, Yandell DW, Dockhorn-Dworniczak B, Wolfe HJ, Poremba C (1993) Androgenrezep-tor-Gen Mutationen und p53-Gen Analyse in fortgeschrittenen Prostata-Karzinomen. Verh Dtsch Ges Pathol 77:119–123.

    PubMed  CAS  Google Scholar 

  41. Cheville JC, Dundore PA, Nascimento AG, Meneses M, Kleer E, Farrow GM, Bostwick DG (1995) Leiomyosarcoma of the prostate. Report of 23 cases. Cancer 76:1422–1427.

    PubMed  CAS  Google Scholar 

  42. Cohen R, Glezerson O, Haffejee Z (1991) Neuroendocrine cells: a new prognostic parameter in prostate cancer. Br J Urol 68: 258–262.

    PubMed  CAS  Google Scholar 

  43. Dawson NA, Wilding G, Weiss RB, Mcleod DG, Linehan WM, Frank JA et al. (1992) A pilot study of chemohormonal therapy for metastatic prostate cancer. Cancer 69: 213–218.

    PubMed  CAS  Google Scholar 

  44. De La Monte SM, Moore GW, Hutchins GM (1986) Metastatic behaviour of prostate cancer. Cluster analysis of pattern with respect to estrogen treatment. Cancer 58: 985–993.

    Google Scholar 

  45. De Las Morenas A, Siroky MB, Merriam J, Stilmant MM (1988) Prostatic adenocarcinoma: reproducibility and correlation with clinical stages of four grading systems. Hum Pathol 19: 595–597.

    Google Scholar 

  46. Denholm SW, Webb JN, Howard GCW, Chisholm GD (1992) Basaloid carcinoma of the prostate gland: histogenesis and review of the literature. Histopathol 20:151–155.

    CAS  Google Scholar 

  47. Devaraj LT, Bostwick DG (1993) Atypical basal cell hyperplasia of the prostate. Immunophenotypic profile and proposed classification of basal cell proliferations. Am J Surg Pathol 17: 645–659.

    CAS  Google Scholar 

  48. Dhom G (1981) Pathologie des Prostatakarzinoms. Verh Dtsch Ges Pathol 32: 9–16.

    Google Scholar 

  49. Dhom G(1991) Prostata In: Doerr W, Seiffert G (Hrsg) Pathologie des männlichen Genitale, Bd 21. Springer, Berlin Heidelberg New York, S 455–642.

    Google Scholar 

  50. Di Sant’Agnese PA (1992) Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic and therapeutic implications. Cancer 70: 254–268.

    PubMed  Google Scholar 

  51. Di Sant’Agnese PA (1992) Neuroendocrine differentiation in human prostatic carcinoma. Hum Pathol 23: 287–296.

    PubMed  Google Scholar 

  52. Di Sant’Agnese PA (1995) Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts. Cancer 75:1850–1859.

    Google Scholar 

  53. Di Sant’Agnese PA, Cockett ATK (1996) Neuroendocrine differentiation in prostatic malignancy. Cancer 78: 357–361.

    PubMed  Google Scholar 

  54. Donn AS, Muir CS (1985) Prostatic cancer. Some epidemiologic features. Bull Cancer (Paris) 72: 381–390.

    CAS  Google Scholar 

  55. Dundore PA, Cheville JC, Nascimento AG, Farrow GM, Bostwick DG (1995) Carcinosarcoma of the prostate. Report of 21 cases. Cancer 76:1035–1042.

    PubMed  CAS  Google Scholar 

  56. Eble JN, Epstein JI (1990) Stage A carcinoma of the prostate. In: Bostwick DG (ed) Pathology of the prostate, seminal vesicles and male urethra. Churchill-Livingstone, New York, pp 61–82.

    Google Scholar 

  57. Effert PJ, Mc Coy RH, Walther PJ, Lin ET (1993) p53 gene alterations in human prostate carcinoma. J Urol 150: 257–261.

    PubMed  CAS  Google Scholar 

  58. Ekman H, Hedberg K, Persson PS (1967) Cytological vs. histological examination of needle biopsy specimens in the diagnosis of prostatic cancer. Br J Urol 39: 544–548.

    PubMed  CAS  Google Scholar 

  59. Elbadawi A, Craig W, Linke CA, Cooper RA Jr (1979) Prostatic mucinous carcinoma. Urol 13: 658–666.

    PubMed  CAS  Google Scholar 

  60. English HF, Kyprianou N, Issacs JT (1989) Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 15: 233–251.

    PubMed  CAS  Google Scholar 

  61. Epstein JI (1990) Evaluation of radical prostatectomy capsular margins of resection. The significance of margins designated as negative, closely approaching and positive. Am J Surg Pathol 14: 626–632.

    PubMed  CAS  Google Scholar 

  62. Epstein JI (1994) The prostate and seminal vesicles. In: Sternberg SS (ed) Diagnostic surgical pathology, vol 2,2nd edn. Raven, New York, pp 1807–1853.

    Google Scholar 

  63. EpsteinJI (1995) Benign and malignant prostate following treatment. In: Silverberg SG (ed) Prostate biopsy interpretation, 2nd edn. Lippincott-Raven, Philadelphia New York, pp 191–203.

    Google Scholar 

  64. Epstein JI (1995) Mesenchymal tumors and tumor-like conditions. In: Silverberg SG (ed) Prostate biopsy interpretation, 2nd edn. Lippincott-Raven, Philadelphia New York, pp 235–248.

    Google Scholar 

  65. Epstein JI (1995) Basaloid lesions of the prostate. In: Silverberg SG (ed) Prostate biopsy interpretation, 2nd edn. Lippincott-Raven, Philadelphia New York, pp 205–220.

    Google Scholar 

  66. Epstein JI (1995) Transitional cell carcinoma. In: Silverberg SG (ed) Prostate biopsy interpretation, 2 nd edn. Lippincott-Raven, Philadelphia New York, pp 221–234.

    Google Scholar 

  67. Epstein JI (1995) Misscellaneous tumors. In: Silverberg SG (ed) Prostate biopsy interpretation, 2nd edn.Lippincott-Raven, Philadelphia New York, pp 249–256.

    Google Scholar 

  68. Epstein JI (1996) The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimens. Cancer 78: 350–356.

    PubMed  CAS  Google Scholar 

  69. Epstein JI (1997) Non-neoplastic diseases of the prostate. In: Bostwick DG, Eble JN (eds) Urologie surgical pathology. Mosby, St. Louis Baltimore Boston, pp 307–340.

    Google Scholar 

  70. Epstein JI, Armas OA (1992) Atypical basal cell hyperplasia of the prostate. Am J Surg Pathol 16: 1205–1214.

    PubMed  CAS  Google Scholar 

  71. Epstein JI, Liebermann PH (1985) Mucinous adenocarcinomas of the prostate gland. Am J Surg Pathol 9: 299–307.

    PubMed  CAS  Google Scholar 

  72. Epstein JI, Sauvageot J (1997) Do close but negative margins in radical prostatectomy specimens increase the risk of postoperative progression? J Urol 157: 241–243.

    PubMed  CAS  Google Scholar 

  73. Epstein JI, Woodruff J (1986) Prostatic carcinomas with endometroid features: a light microscopic and immunohistochemical study of 10 cases. Cancer 57:111–119.

    PubMed  CAS  Google Scholar 

  74. Epstein JI, Kuhajda FP, Liebermann PH (1986) Prostatic specific acid phosphatase immunoreactivity in adenocarcinomas of the urinary bladder. Hum Pathol 17: 939–942.

    PubMed  CAS  Google Scholar 

  75. Epstein JI, Carmichael MJ, Pizov G, Walsh PC (1993) Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long term follow up. J Urol 150: 135–141.

    PubMed  CAS  Google Scholar 

  76. Epstein JI, Pizov G, Walsh PC (1993) Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71: 3582–3593.

    PubMed  CAS  Google Scholar 

  77. Epstein JI, Carmichael M, Partin AW, Walsh PC (1993) Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 149:1478–1481.

    PubMed  CAS  Google Scholar 

  78. Epstein JI, Walsh PC, Carmichael M, Brendler CB (1994) Pathologic and clinical findings to predict tumor extent of non palpable (stage ic) prostate cancer. JAMA 271: 368–374.

    PubMed  CAS  Google Scholar 

  79. Epstein JI, Partin A, Veltri R (1995) Neuroendocrine differentiation (NE) in prostate cancer: enhanced prediction of progression following radical prostatectomy. Lab Invest 72: 75 A.

    Google Scholar 

  80. Epstein JI, Partin AW, Sauvageot J, Walsh PC (1996) Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long term follow up. Am J Surg Pathol 20: 286–292.

    PubMed  CAS  Google Scholar 

  81. Eschenbach AC von (1996) The biologic dilemma of early carcinoma of the prostate. Cancer 78: 326–329.

    Google Scholar 

  82. Eschenbach AC von, Brawer MK, di Sant’Agnese PA, Humphrey PA, Mahran H, Murphey GP et al. (1996) Workgroup 4: Exploration of new pathologic factors in terms of potential for prognostic significance and future applications. Cancer 78: 372–375.

    Google Scholar 

  83. Eschenbach AC von, Ho R, Murphy GP, Cunnuingham M, Lins N (1996) American Cancer Society guidelines for the early detection of prostate cancer: update, June io, 1997. Cancer 80:1805–1807.

    Google Scholar 

  84. Esposti PL, Elman A, Norlen H (1975) Complications of transrectal aspiration biopsy of the prostate. Scand J Urol Nephrol 9: 208–213.

    PubMed  CAS  Google Scholar 

  85. Fell P, O’Connor M, Smith JM (1987) Primary lymphoma of prostate presenting as bladder outflow obstruction. Urology 29: 555–559.

    PubMed  CAS  Google Scholar 

  86. Foucar E, Haake G, Dalton L, Pathak DR, Lujan JP (1993) The area of cancer in transurethral resection specimens as a prognostic indicator in carcinoma of the prostate. Acomputer assisted morphometric study. Hum Pathol 21: 586–592.

    Google Scholar 

  87. Frankel K, Craig JR (1974) Adenoid cystic carcinoma of the prostate. Am J Clin Pathol 62: 639–645.

    PubMed  CAS  Google Scholar 

  88. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S (1994) Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 54: 2861–2864.

    PubMed  CAS  Google Scholar 

  89. Gaudin PB, Epstein JI (1994) Adenosis of the prostate. Histologic features in transurethral resection specimens. Am J Surg Pathol 18: 863–870.

    CAS  Google Scholar 

  90. Geurin D, Hasan N, Keen CE (1993) Signet ring cell differentiation in adenocarcinoma of the prostate: astudy of five cases. Histopathol 22: 367–371.

    Google Scholar 

  91. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC (1992) A prospective cohort study of vasectomy and prostate cancer in US men. JAMA 269: 873–877.

    Google Scholar 

  92. Giovannucci E, Tosteson TD, Speizer FE, Ascherio A, Vassey MP, Colditz GA (1992) A retrospective cohort study of vasectomy and prostate cancer in US men. JAMA 269: 878–882.

    Google Scholar 

  93. Girinsky T, Koumenis C, Graeber TG, Peehl DM, Giaccia AJ (1995) Attenuated response of p53 and p 21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents. Cancer Res 55: 3726–3731.

    PubMed  CAS  Google Scholar 

  94. Giroldi LA, Schalken JA (1993) Decreased expression of the intercellular adhesion molecule E-Cadherin in prostate cancer: biological significance and clinical implications. Cancer Metastasis Rev 12: 29–37.

    PubMed  CAS  Google Scholar 

  95. Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother Rep 50: 125–128.

    PubMed  CAS  Google Scholar 

  96. Gleason DF (1977) The veterans administration cooperative urological research group. Histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaum M (ed) Urologie pathology: the prostate. Lea & Febiger, Philadelphia, pp 171–197.

    Google Scholar 

  97. Gleason DF (1990) Histologic grading of prostatic carcinoma. In: Bostwick DG (ed) Pathology of the prostate. Churchill Livingstone, New York, pp 83–93.

    Google Scholar 

  98. Gleason DF (1992) Histologic grading of prostate cancer: a perspective. Hum Pathol 23: 273–279.

    PubMed  CAS  Google Scholar 

  99. Goel A, Abou-Ellela A, De Rose PB, Cohen C (1996) The prognostic significance of proliferation in prostate cancer. J Urol Pathol 4: 213–225.

    Google Scholar 

  100. Green DR, Egawa S, Neerhut G, Flanagan W, Wheeler TM, Scardino PT (1991) The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer. J Urol 145: 324–329.

    Google Scholar 

  101. Green LF, Farrow GM, Ravits JM, Tomera FM (1979) Prostatic adenocarcinoma of ductal origin. J Urol 121:303–305.

    Google Scholar 

  102. Greschner M, Siegsmund M, Alken P (1997) Genetische Grundlagen hereditärer Erkrankungen Teil 2: maligne Erkrankungen und Syndrome. Akt Urol 28: 4–23.

    Google Scholar 

  103. Grignon D, Caplan R, Sakr W, Porter A, Doggen RLS, John M et al. (1995) Neuroendocrine (NE) differentiation as a prognostic indicator in locally advanced prostate cancer (PCa). Lab Invest 72: 76 A.

    Google Scholar 

  104. Grignon DJ, Hammond EH (1995) College of american pathologists conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the prostate cancer working group. Arch Pathol Lab Med 119: 1122–1126.

    CAS  Google Scholar 

  105. Grignon DJ, Sakr WA (1996) Pathologic staging of prostate carcinoma. Cancer 78: 337–340.

    PubMed  CAS  Google Scholar 

  106. Grignon DJ, Ro JY, Ordonez NG, Ayala AG, Cleary KR (1988) Basal cell hyperplasia, adenoid basal cell tumor and adenoid cystic carcinoma of the prostate: an immunohistochemical study. Hum Pathol 19: 1425–1433.

    PubMed  CAS  Google Scholar 

  107. Grignon DJ, Ro JY, Ayala AG, Johnson DE, Ordonez NG (1991) Primary adenocarcinoma of the urinary bladder: clinicopathologic analysis of 72 cases. Cancer 67: 2165–2172.

    PubMed  CAS  Google Scholar 

  108. Hall GS, Kramer CE, Walsh PC, Epstein JI (1992) Evaluation of radical prostatectomy specimens: a comparative analysis of various sampling methods. Am J Surg Pathol 16: 315–324.

    PubMed  CAS  Google Scholar 

  109. Hall MC, Troncoso P, Pollack A, Zhau HYE, Zagars GK, Chung LWK, von Eschenbach AC (1994) Significance of tumor angioneogenesis in clinically localised prostate carcinoma treated with external beam radiotherapy. Urol 44: 869–875.

    PubMed  CAS  Google Scholar 

  110. Hammerer P, Huland H, Sparenberg S (1992) Digital rectal examination, imaging and systematic-sextant biopsy in identifying operable lymph node negative prostatic carcinoma. Eur Urol 22: 281–287.

    PubMed  CAS  Google Scholar 

  111. Hanchette CL, Schwartz GG (1992) Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolett radiation. Cancer 70: 2861–2869.

    CAS  Google Scholar 

  112. Hanke P, Gotting B, Burk K, Schneider M, Weber W (1987) Prognose und Beurteilung von Prostatakarzinomen. Ein Vergleich der Klassifikation nach Dhom und der kombinierten histologisch–zytologischen Klassifikation des onkologischen Arbeitskreises Prostatakarzinom. Verh Dtsch Ges Urol 38:216–218.

    Google Scholar 

  113. Hedrick L, Epstein JI (1989) Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 13: 389–396.

    PubMed  CAS  Google Scholar 

  114. Heipap B (1989) Do precursor lesions of prostatic carcinoma exist? World Urol 7: 27–33.

    Google Scholar 

  115. Heipap B (1989) Prostata. In: Heipap B (Hrsg) Pathologie der ableitenden Harnwege und der Prostata. Springer, Berlin Heidelberg New York, S 161–354.

    Google Scholar 

  116. Heipap B (1991) Atypical hyperplasia, intraepithelial neoplasia and incidental carcinoma of the prostate. In: Altwein JE, Faul P, Schneider W (eds) Incidental carcinoma of the prostate. Springer, Berlin Heidelberg New York, pp 74–91.

    Google Scholar 

  117. Heipap B (1993) Review of the morphology of prostatic carcinoma with special emphasis of sub-grading and prognosis. J Urol Pathol 1: 13–19.

    Google Scholar 

  118. Heipap B, Weißbach L (1984) Retrospektive Untersuchungen über Behandlung und Verlauf des Prostatakarzinoms auf der Basis eines histologisch-zytologischen Gradings. Verh Dtsch Ges Path 68: 376.

    Google Scholar 

  119. Heipap B, Bostwick DG, Montironi R (1995) The significance of atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia for the development of prostate carcinoma. Virch Arch 426: 425–434.

    Google Scholar 

  120. Henson DE, Hutter RVP, Farrow GM (1994) Practise protocol for the examination of specimens removed from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 118: 779–783.

    PubMed  CAS  Google Scholar 

  121. Heyderman E, Brown VE, Richardson TC (1984) Epithelial markers in prostatic, bladder and colorectal cancer: an immunoperoxidase study of epithelial membrane antigen, carcinoembryonic antigen and prostatic acid phosphatase. J Clin Pathol 37: 1363–1369.

    PubMed  CAS  Google Scholar 

  122. Honn KV, Aref A, Chen YQ, Cher ML, Crissman JD, Forman JD et al. (1996) Prostate cancer. Old problems and new approaches Part II. Diagnostic and prognostic markers, pathology and biological aspects. Pathol Oncol Res 2: 191–211.

    PubMed  CAS  Google Scholar 

  123. Hsing AW, Mc Laughlin JK, Hrubec Z, Blot WJ, Fraumeni JF Jr (1991) Tobacco use and prostate cancer: 26 year follow up of US-veterans. Am J Epidemiol 133: 437–441.

    PubMed  CAS  Google Scholar 

  124. Hutter RVP, Montie JE, Busch CH, Grignon DJ, Lieber M, Logothetis CH et al. (1996) Workgroup 3: Current prognostic factors and their relevance to staging. Cancer 78: 369–371.

    PubMed  CAS  Google Scholar 

  125. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF (1992) Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 13: 457–464.

    PubMed  CAS  Google Scholar 

  126. Isaacs WB, Bova GS, Morton RA, Bussemakers MJ, Brooks JD, Ewing CM (1994) Molecular biology of prostate cancer. Seminar Oncol 21: 514–521.

    CAS  Google Scholar 

  127. Johnson DE, Chalbaud R, Ayala AG (1974) Secondary tumors of the prostate. J Urol 112: 507–508.

    PubMed  CAS  Google Scholar 

  128. Kahane H, Sharp JW, Shuman GB, Dasilva G, Epstein JI (1995) Utilisation of high molecular weight cytokeratin on prostate biopsies in an independent laboratory. Urol 45: 981–986.

    PubMed  CAS  Google Scholar 

  129. Kang F, Chung-Fu P (1983) Predicting the probability of bone metastasis through histological grading of prostate carcinoma: a retrospective correlative analysis of 81 autopsy cases with ante-mortem transurethral resection specimen. J Urol 130: 708–711.

    Google Scholar 

  130. Kastendieck H (1987) Klinisches vs. inzidentes Prostatakarzinom: pathomorphologische Aspekte als Therapiegrundlage. In: Nagel R (Hrsg) Konservative Therapie des Prostatakarzinoms. Springer, Berlin Heidelberg New York, S 1–19.

    Google Scholar 

  131. Kastendieck H, Hüsselmann H (1982) Postoperative pathomorphologische Klassifikation des Prostatakarzinoms. Empfehlungen zur Bearbeitung totaler Prostatektomien und Relevanz der Befunde. Pathologe 3: 278–286.

    CAS  Google Scholar 

  132. Kastendieck H, Bressel M, Henke A, Hüsselmann H (1980) Häufigkeit regionärer Lymphknotenmetastasen beim operablen Prostatakarzinom. DMW 105: 1348–1354.

    CAS  Google Scholar 

  133. Keeley FX, Gomella LG (1996) Chapter 1: Epidemiology of prostate cancer. In: Ernsthoff MS, Heaney JA, Peschel RE (eds) Urologie cancer. Blackwell, Cambridge/MA Oxford London, pp 2–14.

    Google Scholar 

  134. Keetch D, Catalona W (1991) Familial aspects of prostate cancer: a case -control review. J Urol 145: 250 A.

    Google Scholar 

  135. Keillor JS, Aterman K (1987) The response of poorly differentiated prostatic tumors to staining for prostate specific antigen and prostate acid phosphatase: a comparative study. J Urol 137: 894–898.

    PubMed  CAS  Google Scholar 

  136. Kerr WK, Keresteci AG, Mayoh H (1960) The distribution of zinc within the human prostate. Cancer 13:550–554.

    PubMed  CAS  Google Scholar 

  137. Key T (1995) Risk factors for prostate cancer. Cane Surv 23: 67–77.

    Google Scholar 

  138. Kopper B, Dhom G, Schwaiger R, Neisius D, Ziegler M (1986) Erfahrungen mit der pelvinen Lymphadenektomie beim Prostatakarzinom. Akt Urol 17: 129–133.

    Google Scholar 

  139. Kost LV, Evans GW (1964) Occurrence and significance of striated muscle within the prostate. J Urol 92: 703–704.

    PubMed  CAS  Google Scholar 

  140. Kyprianou N, English SH, Issacs JT (1988) Activation of a Ca 2+ -Mg 2+ - dependent endonuclea–se as an early event in castration-induced prostatic cell death. Prostate 13: 103–118.

    PubMed  CAS  Google Scholar 

  141. Lange PH (1995) Editorial: a potpourri of new observations about prostate cancer. J Urol 153: 1009–1010.

    PubMed  CAS  Google Scholar 

  142. Lee SS (1994) Endometroid adenocarcinoma of the prostate. A clinicopathologic and immunohistochemical study. J Surg Oncol 55: 235–238.

    CAS  Google Scholar 

  143. Leistenschneider W, Nagel R (1980) Zytologisches Regressionsgrading und seine prognostische Bedeutung beim konservativ behandelten Prostatakarzinom. Akt Urol 11: 263–275.

    Google Scholar 

  144. Lepor H, Gregerman M, Crosby R, Mostofi FK, Walsh PC (1985) Precise localisation of the autonomic nerves from the pelvic plexus to the corpora cavernosa: a detailed anatomical study of the adult male pelvis. J Urol 133: 207–212.

    PubMed  CAS  Google Scholar 

  145. MacGrogan D, Levy A, Bostwick D, Wagner M, Bookstein R (1994) Loss of chromosome arm 8 p loci in prostate cancer: mapping by quantitative allelic balance. Genes Chomosom Cancer 10: 151–159.

    CAS  Google Scholar 

  146. Mahadevia PS, Koss LG, Tar IJ (1986) Prostatic involvement in bladder cancer: prostatic mapping in 20 cystoprostatectomy specimens. Cancer 58: 2096–2102.

    PubMed  CAS  Google Scholar 

  147. Manley CB Jr (1966) The striated muscle of the prostate. J Urol 95: 234–240.

    PubMed  Google Scholar 

  148. Mashal RD, Lester S, Corless C, Riechie JP, Chandra R, Propert KJ, Dutta A (1996) Expression of cell cycle-regulated proteins in prostate cancer. Cancer Res 56: 4159–4163.

    PubMed  CAS  Google Scholar 

  149. McNeal JE (1980) Anatomy of the prostate: a historical survey of divergent views. Prostate 1: 3–13.

    PubMed  CAS  Google Scholar 

  150. McNeal JE (1981) Normal and pathologic anatomy of prostate. Urol 17 (Suppl): 11–16.

    PubMed  CAS  Google Scholar 

  151. McNeal JE (1992) Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol 23: 258–266.

    PubMed  CAS  Google Scholar 

  152. McNeal JE, Redwine EA, Freiha FS, Stamey TA (1988) Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol 12: 897–906.

    PubMed  CAS  Google Scholar 

  153. McNeal JE, Villers A, Redwine EA, Freiha FS, Stamey TA (1990) Histologic differentiation, cancer volume and pelvic lymphnode metastasis in adenocarcinoma of the prostate. Cancer 66: 1225–1233.

    PubMed  CAS  Google Scholar 

  154. McNeal JE, Alroy J, Villers A, Redwine EA, Freiha FS, Stamey TA (1991) Mucinous differentiation in prostatic adenocarcinoma. Hum Pathol 22: 979–988.

    PubMed  CAS  Google Scholar 

  155. Meikle AW, Smith JA (1990) Epidemiology of prostate cancer. Urol Clin North Am 17: 709–718.

    PubMed  CAS  Google Scholar 

  156. Mellon K, Thompson S, Charlton RG, Marsh C, Robinson M, Lane DP et al. (1992) P53, c-erb B-2 and the epidermal growth factor receptor in the benign and malignant prostate. J Urol 147: 496–499.

    PubMed  CAS  Google Scholar 

  157. Mettlin C, Natarajan N, Huben R (1990) Vasectomy and prostate cancer risk. Am J Epidemiol 132: 1056–1061.

    PubMed  CAS  Google Scholar 

  158. Minkowitz G, Peterson P, Godwin TA (1990) A histochemical and immunohistochemical study of adenocarcinoma involving urinary bladder. Mod Pathol 3: 68 A.

    Google Scholar 

  159. Mishina T, Shimada N, Toki J, Ikehara S (1990) A case report of phylloides tumor of the prostate: review of the literature and analysis of bizarre giant cell origin. Acta Urol Jpn 36: 1185–1188.

    CAS  Google Scholar 

  160. Moskovitz B, Munichor M, Bolkier M, Livne PM (1993) Squamous cell carcinoma of the prostate. Urol Int 51: 181–183.

    PubMed  CAS  Google Scholar 

  161. Mott LJM (1979) Squamous cell carcinoma of the prostate. Report of 2 cases and review of the literature. J Urol 121: 833–836.

    PubMed  CAS  Google Scholar 

  162. Mukamel E, Nussbaum B (1992) Fifteen years experience of combined hormone/chemotherapy in metastatic prostate cancer. Urol 39: 274–276.

    PubMed  Google Scholar 

  163. Müller H-A, Altenähr E, Boeking A, Dhom G, Faul P, Göttinger H et al. (1980) Über Klassifikation und Grading des Prostatakarzinoms. Verh Dtsch Ges Path 64: 609–611.

    Google Scholar 

  164. Nakada SY, di Sant’Agnese PA, Moynes RA, Hiipakka RA, Liao S, Cockett AT et al. (1993) The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 53: 1967–1970.

    PubMed  CAS  Google Scholar 

  165. O’Malley FP, Grignon DJ, Shum DT (1990) Usefulness of immunoperoxidase staining with high molecular-weight cytokeratin in the differential diagnosis of small acinar lesions of the prostate gland. Virch Arch A Pathol Anat Histopathol 417: 191–196.

    Google Scholar 

  166. Orell SR, Sterrett GF, Walters MN-I, Whitaker D (1992) Chapter 10: Male and female genital organs. In: Manual and atlas of fine needle aspiration cytology. Churchill Livingstone, Edinburgh London Madrid Melbourne, pp 268–297.

    Google Scholar 

  167. Partin AW, Oesterling JE (1994) The clinical usefulness of prostate specific antigen: update 1994. J Urol 152: 1358–1368.

    PubMed  CAS  Google Scholar 

  168. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, Walsh PC (1993) The use of prostatic specific antigen, clinical stage and gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 110–114.

    PubMed  CAS  Google Scholar 

  169. Petersen RO (1992) Chapter 8: Prostate and seminal vesicles. In: Petersen RO (ed) Urologie pathology, 2nd edn. Lippincott, Philadelphia, pp 575–651.

    Google Scholar 

  170. Pienta KJ, Esper PS (1993) Risk factors for prostate cancer. Ann of Intern Med 118: 793–803.

    CAS  Google Scholar 

  171. Pienta KJ, Esper PS (1993) Is dietary fat a risk factor for prostate cancer? J Natl Cancer Inst 85: 1538–1540.

    PubMed  CAS  Google Scholar 

  172. Prout GR, Heaney JA, Griffin PP, Daly JJ, Shipley WV (1980) Nodal involvement as a prognostic indicator in patients with prostatic carcinoma. J Urol 124: 226–231.

    PubMed  Google Scholar 

  173. Raffo AJ, Perlman H, Chen MW, Day ML, Streitman JS, Buttyan R (1995) Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55: 4438–4445.

    PubMed  CAS  Google Scholar 

  174. Raney RB Jr, Gehan EA, Hays DM, Tefft M, Newton WA Jr, Haeberlen V, Maurer HM (1990) Primary chemotherapy with or without radiation therapy and/or surgery for children with localized sarcoma ofs the bladder, prostate, vagina uterus and cervix. A comparison of the results in inter-group rhabdomyosarcoma studies I and II. Cancer 66: 2072–2081.

    Google Scholar 

  175. Ravery V, Schmid HP, Toublanc M, Boccon-Gibod L (1996) Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1–T2 prostate cancer ? Cancer 78: 1079–1084.

    PubMed  CAS  Google Scholar 

  176. Reese JH, Freiha FS, Gelb AB, Lum BL, Torti FM (1991) Transitional cell carcinoma of the prostate in patients undergoing radical cysto-prostatectomy. J Urol 147: 92–95.

    Google Scholar 

  177. Ro JY, Ayala AG, Wishnow KI, Ordonez NG (1988) Prostatic duct adenocarcinoma with endometroid features: immunhistochemical and electron microscopic study. Semin Diag Pathol 5: 301–311.

    CAS  Google Scholar 

  178. Ro JY, El Naggar A, Ayala AG, Mody DR, Ordonez NG (1988) Signet ring cell carcinoma of the prostate.Electronmicroscopic and immunohistochemical studies of 8 cases. Am J Surg Pathol 12: 453–460.

    PubMed  CAS  Google Scholar 

  179. Ro JY, Grignon J, Ayala AG, Fernandez PL, Ordonez NG, Wishnow KI (1990) Mucinous adenocarcinoma of the prostate: histochemical and immunohistochemical studies. Hum Pathol 21: 593–600.

    PubMed  CAS  Google Scholar 

  180. Rohan TE, Howe GR, Burch JD, Jain M (1995) Dietary factors and risk of prostate cancer: a case-control study in Ontario, Canada. Cane Causes Control 6: 145–154.

    CAS  Google Scholar 

  181. Ross RK, Bernstein L, Judd H, Hanisch R, Pike M, Henderson B (1986) Serum testosteron levels in healthy young black and white man. J Nat Cane Inst 76: 45–48.

    CAS  Google Scholar 

  182. Saarländisches Krebsregister: Prostatakarzinom 1990–1993: Neumeldungen und Sterbefälle.

    Google Scholar 

  183. Sadi MV, Barrack ER (1993) Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Cancer 71: 2574–2580.

    PubMed  CAS  Google Scholar 

  184. Sadi MV, Walsh PC, Barrack ER (1991) Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 67: 3057–3064.

    CAS  Google Scholar 

  185. Saitoh H, Hida M, Shimbo T, Nakamura K, Yamagata J, Satoh T (1984) Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved. Cancer 54: 3078–3084.

    CAS  Google Scholar 

  186. Sakr WA, Haas GP, Cossin BF, Pontes JE, Crissmann JD (1993) The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150: 379–385.

    PubMed  CAS  Google Scholar 

  187. Sakr WA, Grignon DJ, Visscher DW, Wolman SR, Crissman JD (1995) Evaluating the radical prostatectomy specimen: a protocol for establishing prognostic parameters and harvesting fresh tissue samples. J Urol Pathol 3: 355–364.

    Google Scholar 

  188. Sakr WA, Wheeler TM, Blute M, Bodo M, Calle-Rodrigue R, Henson DE et al. (1996) Workgroup 2: staging and reporting of prostate cancer — sampling of the radical prostatectomy specimen. Cancer 78(2): 366–368.

    PubMed  CAS  Google Scholar 

  189. Sanchez Y, Lovell M, Marin MC, Wong PE, Wolf-Ledbetter ME, McDonnell TJ, Killary AM (1996) Tumor suppression and apoptosis of human prostate carcinoma mediated by genetic locus within human chromosome 10 pter-q11. Nat Acad Sei 93: 2551–2556.

    CAS  Google Scholar 

  190. Sarma DP, Weilbaecher TG, Moon TD (1991) Squamous cell carcinoma of prostate. Urol 37: 260–262.

    PubMed  CAS  Google Scholar 

  191. Scardino PT, Frankel JM, Wheeler TM, Meacham RB, Hoffmann GS, Seale C et al. (1986) The prognostic significance of post irradiation biopsy results in patients with prostatic cancer. J Urol 135: 510–516.

    PubMed  CAS  Google Scholar 

  192. Schellhammer PF, Bean MA, Whitmore WF Jr (1977) Prostatic involvement by transitional cell carcinoma: pathogenesis, patterns and prognosis. J Urol 118: 399–403.

    PubMed  CAS  Google Scholar 

  193. Schmid HP, McNeal JE (1992) An abbreviated standard procedure for accurate tumor volume estimation in prostate cancer. Am J Surg Pathol 16: 184–191.

    PubMed  CAS  Google Scholar 

  194. Seidman H, Mushinski MH, Gelb SK, Silverberg E (1985) Probabilities of evetually developing or dying of cancer-United States 1985. CA Cancer J Clin 35: 36–56.

    PubMed  CAS  Google Scholar 

  195. Shankey TV, Kallioniemi O-P, Koslowski JM, Lieber MM, Mayall BH, Miller G, Smith GJ (1993) Consensus review of the clinical utility of DNA content cytometry in prostate cancer. Cytometry 14: 497–500.

    PubMed  CAS  Google Scholar 

  196. Sobin LH, Wittekind CH (1997) Prostate (ICD-O C61). In: Sobin LH, Wittekind CH (eds) TNM Classification of malignant tumors, 5th edn. Wiley-Liss, New York Chichester Weinheim, pp 170–173.

    Google Scholar 

  197. Spires SE, Cibull ML, Wood DP Jr, Miller S, Spires SM, Banks ER (1994) Gleason histologic grading in prostatic carcinoma. Correlation of 18 gauge core biopsy with prostatectomy. Arch Pathol Lab Med 118: 705–708.

    PubMed  CAS  Google Scholar 

  198. Spitz M, Currier R, Fueger JJ, Babaian RJ, Newell GR (1991) Familial patterns of prostate cancer: a case-control analysis. J Urol 146: 1305–1307.

    PubMed  CAS  Google Scholar 

  199. Statistisches Bundesamt (1994): Gesundheitswesen Fachserie 12, Reihe 4 Todesursachen in Deutschland, Wiesbaden.

    Google Scholar 

  200. Steinberg D, Sauvageot J, Epstein JI (1996) Correlation of prostate needle biopsy and radical prostatectomy: gleason grade in academic and community settings. Mod Pathol 9: 83 A.

    Google Scholar 

  201. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J (1993) Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46: 759–765.

    PubMed  CAS  Google Scholar 

  202. Svanholm H (1986) Evaluation of commercial immunoperoxidase kits for prostate specific antigen and prostatic acid phosphatase. Acta Pathol Microbiol Immunol Scand (A) 94: 7–15.

    CAS  Google Scholar 

  203. Takahashi S, Qian J, Brown JA, Alcaraz A, Bostwick DG, Lieber MM, Jenkins RB (1994) Potential markers of prostate cancer aggressiveness detected by fluorescence in situ hybridisation in needle biopsies. Cancer Res 54: 3574–3579.

    PubMed  CAS  Google Scholar 

  204. Terris MK, McNeal JE, Stamey TA (1992) Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 148: 829–832.

    PubMed  CAS  Google Scholar 

  205. Thomas R, Lewis R, Sarma D, Coker GB, Rao MK, Roberts JA (1982) Aid to accurate clinical staging — histopathologic grading in prostatic cancer. J Urol 128: 726–728.

    PubMed  CAS  Google Scholar 

  206. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Oosterhof GO et al. (1992) Expression of the cellular adhesion molecule, E-cadherin, is reduced or absent in high grade prostate cancer. Cancer Res 52: 5104–5109.

    PubMed  CAS  Google Scholar 

  207. Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO et al. (1994) Decreased E-Cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54: 3929–3933.

    PubMed  CAS  Google Scholar 

  208. Vaughan ED (1994) Editorial: localized prostatic cancer: clinical concerns. J Urol 152: 1922.

    PubMed  Google Scholar 

  209. Veldhuizen PJ van, Sadasivan R, Garcia F, Austenfeld MS, Stephens RL (1993) Mutant p53 expression in prostate carcinoma. Prostate 22: 23–30.

    PubMed  Google Scholar 

  210. Viadana E, Bross IDJ, Pickren JW (1978) An autopsy study of the metastatic patterns of human leukemias. Oncol 35: 87–96.

    CAS  Google Scholar 

  211. Villers A, McNeal JE, Freiha FS, Boccon-Gibod L, Stamey SA (1993) Invasion of Denonvilliers’ fascia in radical prostatectomy specimens. J Urol 149: 793–798.

    PubMed  CAS  Google Scholar 

  212. Voeller HJ, Sugars LY, Pretlow T, Gelmann EP (1994) P53 oncogene mutations in human prostate specimens. J Urol 151: 492–495.

    PubMed  CAS  Google Scholar 

  213. Voges GE (1992) Das klinisch organbegrenzte, radikal operierte Adenokarzinom der Prostata: Invasionscharakteristika, Prognosefaktoren sowie ihr Einfluß auf diagnostische und therapeutische Entscheidungen. Habilitationsschrift, Johannes Gutenberg Universität Mainz.

    Google Scholar 

  214. Walsh PC, Lepor H, Eggleston JC (1983) Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 4: 473–485.

    PubMed  CAS  Google Scholar 

  215. Warhol MJ, Longtine JA (1985) The ultrastructural localisation of prostatic specific antigen and prostatic acid phosphatase in hyperplastic and neoplastic human prostates. J Urol 134: 607–613.

    PubMed  CAS  Google Scholar 

  216. Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR et al. (1995) Prostate cancer in relation to diet, physical activity and body size in blacks, whites and asians in the United States and Canada. J Nat Cane Inst 87: 652–661.

    CAS  Google Scholar 

  217. Wingo PA, Landis S, Ries LAG (1997) An adjustment to the 1997 estimate for new prostate cancer cases. Cancer 80: 1810–1813.

    PubMed  CAS  Google Scholar 

  218. Wingo T, Tong T, Bolden S (1995) Cancer statistics 1995. CA Center J Clin 45: 8–30.

    CAS  Google Scholar 

  219. Wojno KJ, Epstein JI (1995) The utility of basal cell specific anticytokeratin antibody (34 beta El2) in the diagnosis of prostate cancer: a review of 228 cases. Am J Surg Pathol 19: 251–260.

    PubMed  CAS  Google Scholar 

  220. Wood DP Jr, Montie JE, Pontes JE, Medendore SV, Levin HS (1989) Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. J Urol 141: 346–349.

    PubMed  Google Scholar 

  221. World Health Organisation (1992) Trends in prostate cancer 1980–1988. WHO Weekly Epidemiol Ree 67: 281–288.

    Google Scholar 

  222. Wright C, Grignon D, Shum D, Porter A (1992) Neuroendocrine differentiation in prostatic adenocarcinoma is not an independent prognostic indicator. Mod Pathol 5: 61 A.

    Google Scholar 

  223. Yang C, Cirielli C, Capogrossi MC, Passaniti A (1995) Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 55: 4210–4213.

    PubMed  CAS  Google Scholar 

  224. Young RH, Frierson HF Jr., Mills SE, Kaiser JS, Talbot WH, Bhan AK (1988) Adenoid cystic-like tumor of the prostate gland. A report of two cases and review of the literature on »adenoid cystic Carcinoma« of the prostate. Am J Clin Pathol 89:49–56.

    PubMed  CAS  Google Scholar 

  225. Zein TA, Huben R, Lane W, Pontes JE, Englander LS (1985) Secondary tumors of the prostate. J Urol 133:615–616.

    PubMed  CAS  Google Scholar 

  226. Zwicke H, Bergstrahl EJ, Larsson-Keller JJ, Farrow GM, Myers RP, Lieber MM et al. (1992) Stage Dl prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Evidence for favorable survivial in patients with DNA diploid tumors. Cancer 70 (Suppl 1): 311–323.

    Google Scholar 

Download references

Authors
  1. R. Golz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Störkel
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Golz, R., Störkel, S. (1999). Pathologische Anatomie maligner Tumoren der Prostata. In: Prostatakarzinom — urologische und strahlentherapeutische Aspekte. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60064-7_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60064-7_1

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64241-8

  • Online ISBN: 978-3-642-60064-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation